EFM
DNLI icon

E Fund Management’s Denali Therapeutics DNLI Stock Holding History

E Fund Management’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$349K Sell
13,585
-5,357
-28% -$110K 0.01% 357
2026
Q1 		$364K Buy
+18,942
New +$377K 0.01% 348
2025
Q2 		$190K Buy
13,612
+1,543
+13% +$21.7K 0.01% 363
2025
Q1 		$164K Buy
12,069
+2,072
+21% +$39.7K 0.01% 372
2024
Q4 		$204K Buy
9,997
+2,436
+32% +$62.4K 0.01% 363
2024
Q3 		$220K Sell
7,561
-1,639
-18% -$40.6K 0.01% 308
2024
Q2 		$214K Sell
9,200
-11,352
-55% -$218K 0.01% 278
2024
Q1 		$422K Buy
20,552
+3,262
+19% +$61.3K 0.03% 197
2023
Q4 		$371K Buy
17,290
+5,509
+47% +$109K 0.02% 202
2023
Q3 		$243K Sell
11,781
-1,580
-12% -$40.1K 0.02% 229
2023
Q2 		$394K Sell
13,361
-1,258
-9% -$35.4K 0.03% 175
2023
Q1 		$337K Sell
14,619
-242
-2% -$6.66K 0.02% 210
2022
Q4 		$413K Buy
14,861
+607
+4% +$18.1K 0.03% 174
2022
Q3 		$437K Buy
14,254
+2,613
+22% +$85K 0.04% 159
2022
Q2 		$343K Buy
11,641
+2,814
+32% +$73.7K 0.03% 210
2022
Q1 		$284K Buy
+8,827
New +$304K 0.01% 214

Other funds holding DNLI

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

E Fund Management's DNLI Position: Q2 2026 in Review

E Fund Management reduced its Denali Therapeutics (DNLI) stake by 28% in Q2 2026, selling an estimated $110K and leaving 13,585 shares worth $349K. The position accounts for 0.01% of the portfolio, ranked #357.

E Fund Management first reported a position in DNLI in Q1 2022 and has held it in 16 quarters since. The position peaked at $437K in Q3 2022. 292 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.

  • E Fund Management held 13,585 shares of Denali Therapeutics worth $349K as of Q2 2026.
  • E Fund Management sold 5,357 Denali Therapeutics shares in Q2 2026, an estimated $110K.
  • Denali Therapeutics made up 0.01% of E Fund Management's portfolio in Q2 2026, its #357 holding.
  • E Fund Management first reported a position in Denali Therapeutics in Q1 2022 and has held it in 16 quarters since.
  • E Fund Management's Denali Therapeutics position peaked at $437K in Q3 2022.
  • 292 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.

Based on E Fund Management's 13F filing for Q2 2026, filed 11 Aug 2026.